Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xilonix · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo administered intravenously every 2 weeks |
| Xilonix | ACTIVE_COMPARATOR | Xilonix administered intravenously every 2 weeks |
| open label-Xilonix | EXPERIMENTAL | Open label-Xilonix |
| Name | Type | Description |
|---|---|---|
| Xilonix | BIOLOGICAL | - |
| Placebo | BIOLOGICAL | - |
Inclusion Criteria: 1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have failed both an oxaliplatin (oxaliplatin may have been in the adjuvant setting) and an i...
Xilonix is a monoclonal antibody that has been studied for symptomatic colorectal cancer and pyoderma gangrenosum. It is an investigational drug developed by Johnson & Johnson and is not approved by the FDA. Clinical trials have evaluated its use in these conditions.
Xilonix is a monoclonal antibody, but its specific molecular target has not been disclosed. It has been studied as an anticancer therapy in symptomatic colorectal cancer and for pyoderma gangrenosum, a skin condition.
Xilonix is developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational monoclonal antibody and has not received regulatory approval.
Xilonix has completed a Phase 2 clinical trial for pyoderma gangrenosum and a Phase 3 clinical trial for symptomatic colorectal cancer. Both trials are completed, and the drug remains investigational, with no FDA approval.
Xilonix has been studied in two completed clinical trials. NCT01965613 was a Phase 2 open-label study in 10 patients with pyoderma gangrenosum in the United States. NCT02138422 was a Phase 3 study in 276 patients with symptomatic colorectal cancer in Poland.
Xilonix is the drug name used in clinical trials for this investigational monoclonal antibody. No alternative names have been reported for this drug in the context of its development for symptomatic colorectal cancer and pyoderma gangrenosum.